Emerging therapeutic options in inflammatory bowel disease

doi:10.3748/wjg.v27.i48.8242

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 48

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5795)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

463

WORD

103

HTML

3710

Figures (1-1)

240

Tables (1-1)

225

Sum=4741

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

334

Download

720

Sum=1054

Dec 28, 2021 (publication date) through Apr 19, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Dec 28, 2021; 27(48): 8242-8261
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8242

Table 1 Phase of clinical trials for emerging therapeutic options for inflammatory bowel

Treatment	UC	CD	Treatment	UC	CD	Treatment	UC	CD	Treatment	UC	CD
Anti-IL			Anti-integrin			JAK inhibitors			Other therapies
Rizankinumab	III	III	Ontamalimab	III	II	Upadacitinib	III	III	AVX-470	I
Mirikizumab	III	II	Etrolizumab	III	III	Filgotinib	III	III	Laquinimod	-	II
Brazikumab	II	III	Abrilumab	II	II	Peficitinib	II	-	Cobitolimod	III	-
Guselkumab	II	III	AJM300	III	-	TD-1473	II	II	BL-7040	II	-
Briakinumab	-	II	Cytokine blockade			Modulation of SIP1			Phosphatidylcholine	III	-
PTG‑200	-	II	Vercirnon	-	III	Ozanimod	III	III	Apremilast	II	-
Secukinumab	-	II	Eldelumab	II	II	Etrasimod	III	-	Mongersen	-	II
Brodalumab	-	II	GSK3050002	I	-	Amiselimod	-	II	GATA3 DNAzyme	II	-
PF-04236921	-	II				KRP-203	II	-	STNM01	II

UC: Ulcerative colitis; CD: Crohn´s disease; IL: Interleukin; JAK: Janus kinase; S1P1: Sphingosine-1-phosphate.

Citation: Yamamoto-Furusho JK, Parra-Holguín NN. Emerging therapeutic options in inflammatory bowel disease. World J Gastroenterol 2021; 27(48): 8242-8261
URL: https://www.wjgnet.com/1007-9327/full/v27/i48/8242.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i48.8242